Which startups have raised the most funding in the femtech market?
Download our beautiful pitch about the femtech market

In our femtech market deck, you will find everything you need to understand the market
The femtech market now spans digital healthcare, fertility, maternal care, menopause, diagnostics, reproductive medicine, medical devices, and women's health biotechnology.
This ranking tracks 98 femtech startups and ranks each company by the cumulative amount of equity funding raised.
We update this list every month so the ranking reflects new funding rounds, acquisitions, and other important changes across the femtech market.
And if you want to better understand this new industry, you can download our pitch covering the femtech market.
A quick summary table
| Metric | Value |
|---|---|
| Most funded femtech startup | Maven Clinic, $414M |
| Second most funded femtech startup | Flo Health, $271M |
| Largest femtech funding round | Flo Health, $200M Series C |
| Median femtech startup funding | $21.5M |
| Share of funding captured by the top 10 | 48.3% |
| Median time since last round | About 2.2 years |
| Startups that raised funding in the last 12 months | 19 |
| Total femtech funding represented | About $4.51B |
| Femtech startups with $100M+ raised | 13 |
| Share of femtech funding captured by the top 3 | 20.8% |

This chart, included in our femtech market deck, shows annual VC investment in femtech startups
Top startups in the femtech market ranked by total funding raised
Here is an updated table that ranks the top startups in the femtech market based on the total amount of funding they have raised to date.
The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).
If you're interested in knowing how much these startups are worth, you can check our list of the top startups in the femtech market ranked by valuation.
| # | Startup | What They Do | Total Raised ($) | Total Rounds | Last Round Date | Last Round Amount ($) | Last Round Type | Key Investors | Current Stage | Confidence |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Maven Clinic | Virtual women’s and family healthcare | $414M | 8 | October 2024 | $125M | Series F | StepStone Group, General Catalyst, Sequoia Capital | Active | Strong |
| 2 | Flo Health | Women’s reproductive health tracking app | $271M | 6 | July 2024 | $200M | Series C | General Atlantic | Active | Strong |
| 3 | Midi Health | Virtual menopause and midlife healthcare | $252M | 6 | February 2026 | $100M | Series D | Goodwater Capital, Foresite Capital, Serena Ventures | Active | Full |
| 4 | TMRW Life Sciences | Automated IVF specimen cryostorage technology | $239M | 5 | March 2026 | $62M | Series E / E-1 | Undisclosed | Acquired | Strong |
| 5 | Willow | Wearable smart breast pumps | $211M | 9 | January 2024 | $81M | Series D extension | Lightstone Ventures | Active | Partial |
| 6 | Kindbody | Fertility clinics and employer benefits | $177M | 8 | May 2023 | $25M | Venture Equity | Morgan Health | Active | Partial |
| 7 | Pomelo Care | Virtual maternal and children’s healthcare | $171M | 4 | January 2026 | $92M | Series C | Stripes, Andreessen Horowitz, Atomico | Active | Full |
| 8 | Elvie | Connected women’s health devices | $158M | 5 | April 2024 | $12M | Late-stage Venture | Undisclosed | Acquired | Strong |
| 9 | Advantia Health | Integrated women’s healthcare provider | $152M | 8 | May 2025 | $5M | Series C extension | Undisclosed | Active | Low |
| 10 | Tia | Hybrid primary healthcare for women | $133M | 4 | September 2021 | $100M | Series B | Lone Pine Capital, Threshold Ventures, Define Ventures | Active | Full |
| 11 | Mercy BioAnalytics | Early cancer liquid biopsy diagnostics | $127M | 3 | September 2025 | $59M | Series B | Novalis, Sozo Ventures, Perceptive Xontogeny | Active | Full |
| 12 | Gameto | Fertility biotechnology company | $117M | 5 | August 2025 | $44M | Series C | Overwater Ventures, Insight Partners, RA Capital | Active | Full |
| 13 | Comanche Biopharma | Preeclampsia RNA therapeutics | $111M | 2 | January 2024 | $75M | Series B | NEA, Atlas Venture, GV | Active | Strong |
| 14 | Natural Cycles | Digital non-hormonal contraception app | $99M | 5 | May 2024 | $55M | Series C | Lauxera Capital Partners, Point72, EQT Ventures | Active | Strong |
| 15 | Ava | Fertility tracking wearable platform | $80M | 5 | Month unknown 2023 | Undisclosed | Venture | B Capital, Swisscom Ventures | Active | Strong |
| 16 | Conceivable Life Sciences | Automates IVF laboratories with robotics | $70M | 3 | July 2026 | Undisclosed | Corporate Minority | IVIRMA Global | Active | Strong |
| 17 | Gesynta Pharma | Endometriosis anti-inflammatory therapeutics | $65M | 6 | October 2025 | $4M | Series B Extension | XGEN Venture | Active | Strong |
| 18 | ReproNovo | Reproductive medicine drug development | $65M | 1 | May 2025 | $65M | Series A | Jeito Capital, AXA IM Alts, M Ventures | Active | Full |
| 19 | Materna Medical | Pelvic and obstetric medical devices | $60M | 5 | June 2026 | $5M | Series B3 | InnovaHealth Partners, Wavemaker 360, Band of Angels | Active | Partial |
| 20 | Peppy | Employer women's health benefits platform | $57M | 4 | January 2023 | $45M | Series B | AlbionVC, MTech Capital, Sony Innovation Fund | Active | Strong |
| 21 | Freya Biosciences | Reproductive microbiome immunotherapy drug development | $50M | 2 | November 2024 | $12M | Series A Extension | Gates Foundation, EIFO | Active | Full |
| 22 | Future Family | Fertility care and IVF financing | $48M | 4 | April 2022 | $25M | Series B | Munich Re Ventures, TriVentures, MS&AD Ventures | Active | Partial |
| 23 | May Health | PCOS infertility treatment devices | $48M | 3 | March 2026 | $12M | Venture / Series B Follow-on | Nexpring Health, Sofinnova Partners, Bpifrance | Active | Full |
| 24 | Clue | Menstrual health tracking app | $47M | 6 | April 2023 | $9M | Equity Crowdfunding | Crowdcube, Adjacent | Active | Strong |
| 25 | PinkDx | Gynecologic cancer diagnostic testing | $45M | 2 | January 2025 | $5M | Series A Extension | Blue Venture Fund, Sandbox Clinical Ventures, BEVC | Active | Full |
| 26 | Inito | At-home fertility hormone diagnostics | $44M | 5 | December 2025 | $29M | Series B | Bertelsmann India Investments, Fireside Ventures | Active | Partial |
| 27 | Clairity | AI breast cancer risk prediction | $43M | 3 | November 2025 | $43M | Series B | ACE Global Equity, Santé Ventures, BCRF | Active | Partial |
| 28 | Renovia | Pelvic floor health devices | $43M | 4 | Month unknown 2021 | $12M | Venture | Perceptive Advisors | Acquired | Strong |
| 29 | Babyscripts | Digital maternal care platform | $40M | 4 | Month unknown 2022 | $11M | Venture Round | Philips Ventures, healthcare investors | Active | Partial |
| 30 | Teal Health | At-home cervical cancer screening | $38M | 4 | August 2026 | $18M | Series A | Not publicly disclosed | Active | Strong |
| 31 | illumigyn | Digital gynecological imaging and diagnostics | $38M | 2 | November 2021 | $33M | Series A | Yozma Group Korea, Ubicom Holdings | Active | Full |
| 32 | Gaia Fertility | Fertility care financing and protection | $37M | 3 | January 2025 | $14M | Venture / Series A extension | Valar Ventures, Atomico, Heliad | Active | Full |
| 33 | HerMD | Specialized menopause and sexual healthcare | $36M | 4 | July 2024 | $8M | Series A Extension | Tarus Capital, JAZZ Venture Partners | Acquired | Partial |
| 34 | Diana Health | Modern women’s healthcare clinics | $34M | 3 | Month unknown 2022 | $34M | Series A | .406 Ventures, AlleyCorp | Active | Strong |
| 35 | Stork Club | Family fertility benefits platform | $33M | 2 | June 2021 | $30M | Series A | General Catalyst, Synetro Group | Active | Full |
| 36 | AOA Dx | Early ovarian cancer blood testing | $32M | 4 | October 2025 | $8M | Series B Extension | Easton Capital | Active | Partial |
| 37 | Alife Health | AI IVF optimization software | $32M | 2 | March 2022 | $22M | Series A | Union Square Ventures, Fantastic Partners | Active | Full |
| 38 | Oula | Maternity care clinics | $28M | 3 | Month unknown 2024 | $6M | Venture Round | Revolution Ventures, Collaborative Fund | Active | Strong |
| 39 | Caraway Health | Gen Z virtual healthcare platform | $27M | 2 | June 2023 | $17M | Series A | Maveron, GV, 7wireVentures | Acquired | Full |
| 40 | Cayaba Care / Nadia Care | Community-based maternal care | $27M | 4 | March 2026 | $12M | Series B | Valtruis, First Trust Capital Partners, RH Capital | Active | Strong |
| 41 | AIVF | AI embryo analysis platform | $26M | 2 | June 2022 | $25M | Series A | Insight Partners, Acrew Capital | Active | Full |
| 42 | Allara Health | Virtual chronic women’s care | $25M | 3 | Month unknown 2024 | $12M | Series A Extension | GV, Threshold Ventures | Active | Strong |
| 43 | Bloomlife | Maternal health wearable monitoring | $25M | 5 | September 2024 | $12M | Series A | Kapor Capital, Noshaq | Active | Strong |
| 44 | Evernow | Menopause telehealth platform | $25M | 3 | Month unknown 2023 | $8M | Venture | Bessemer Venture Partners | Active | Strong |
| 45 | Alpha Medical | Digital women’s healthcare clinic | $24M | 3 | Month unknown 2020 | $10M | Venture | Oak HC/FT | Acquired | Partial |
| 46 | Ataraxis AI | AI-powered precision cancer diagnostics | $24M | 2 | March 2025 | $20M | Series A | AIX Ventures, Founders Fund, Thiel Bio | Active | Full |
| 47 | Vara | AI breast cancer screening | $24M | 4 | October 2024 | $9M | Venture / Growth | Smart Family Office, FJH, IBB Ventures | Active | Strong |
| 48 | MobileODT | Mobile cervical cancer screening | $23M | 5 | August 2020 | $4M | Series C | OrbiMed, Tristel, Tara Health | Acquired | Partial |
| 49 | Delfina | AI-powered maternal care platform | $22M | 2 | January 2025 | $17M | Series A | USVP, ARTIS Ventures, Mayo Clinic | Active | Full |
| 50 | OCON Healthcare | Intrauterine drug delivery medical devices | $21M | 6 | June 2024 | $10M | Series A | RH Capital, Features Capital, Astia Angels | Active | Partial |
| 51 | Twentyeight Health | Women’s telehealth services | $20M | 4 | Month unknown 2024 | $2M | Venture Round | RH Capital, SteelSky Ventures | Active | Strong |
| 52 | Wildflower Health | Digital women’s health platform | $20M | 3 | Month unknown 2021 | $3M | Strategic Equity | Anthem Ventures | Active | Partial |
| 53 | Alloy Women's Health | Menopause telehealth and hormone care | $19M | 2 | December 2024 | $16M | Series A | Kairos HQ, Amboy Street Ventures, PACE Healthcare Capital | Active | Strong |
| 54 | Evvy | Vaginal microbiome testing and care | $19M | 2 | September 2023 | $14M | Series A | Left Lane Capital, General Catalyst, RH Capital | Active | Full |
| 55 | Millie | Hybrid maternity and gynecology clinics | $19M | 2 | February 2025 | $12M | Series A | TMV, Foreground Capital, Pivotal Ventures | Active | Strong |
| 56 | Sonio | AI prenatal ultrasound software | $19M | 2 | July 2023 | $14M | Series A | Cross-Border Impact Ventures, EIC Fund, Elaia | Acquired | Strong |
| 57 | inne | Saliva-based hormone monitoring | $19M | 3 | December 2025 | Undisclosed | Series A-III | Calm/Storm Ventures | Active | Partial |
| 58 | NextGen Jane | Menstrual blood molecular diagnostics | $18M | 3 | October 2023 | $7M | Series A-II | Material Impact | Active | Strong |
| 59 | Daye | Gynecological diagnostics and period care | $17M | 2 | October 2022 | $12M | Series A | Hambro Perks, MassMutual Ventures, Cross-Border Impact Ventures | Active | Partial |
| 60 | Visana Health | Virtual women’s health clinic | $16M | 3 | Month unknown 2024 | $5M | Venture Round | Flare Capital Partners, .406 Ventures | Active | Strong |
| 61 | Mahmee | Pregnancy and postpartum care platform | $15M | 6 | December 2023 | $2M | Series A-II | MaC Venture Capital, Muse Capital | Active | Partial |
| 62 | Overture Life | Automated IVF technology | $15M | 2 | Month unknown 2021 | $10M | Venture | SOSV, IndieBio | Active | Partial |
| 63 | Womed | Intrauterine therapies for uterine disorders | $15M | 2 | July 2026 | $8M | Venture / Equity Crowdfunding | IRDI Capital, CEMAG, Cantrak | Active | Strong |
| 64 | Vira Health | Personalized digital menopause care | $14M | 2 | March 2022 | $12M | Series A | Octopus Ventures, Optum Ventures | Active | Full |
| 65 | Hertility Health | Reproductive hormone testing and care | $13M | 3 | October 2024 | Undisclosed | Angel | Emma Watson | Active | Partial |
| 66 | Oova | At-home fertility hormone monitoring | $13M | 4 | June 2023 | $10M | Series A | Spero Ventures, US Fertility, Virgin Group | Active | Partial |
| 67 | Univfy | AI-powered IVF success prediction | $13M | 4 | December 2021 | $6M | Series B | Atlantic Street Capital | Active | Low |
| 68 | Cofertility | Egg freezing and donation platform | $12M | 2 | April 2025 | $7M | Series A | Next Ventures, Offline Ventures, Initialized Capital | Active | Full |
| 69 | Elektra Health | Virtual menopause care and education | $12M | 4 | February 2025 | $5M | Series Unknown | Catalyst by Wellstar | Active | Strong |
| 70 | Gynoveda | Ayurvedic reproductive health platform | $11M | 2 | March 2023 | $10M | Series A | India Alternatives Fund, Wipro Enterprises, RPG Ventures | Active | Full |
| 71 | Lady Technologies | Cervical-fluid fertility tracking device | $11M | 3 | January 2025 | $7M | Series A | Relentless Consumer Partners, QQ Capital, SOSV | Active | Full |
| 72 | Plenna | Hybrid women’s healthcare clinics | $11M | 3 | June 2025 | $6M | Series A | Dalus Capital, Mazapil Capital, New Ventures Capital | Active | Strong |
| 73 | Hormona | At-home hormone tracking and insights | $10M | 2 | May 2025 | $7M | Seed | Voima Ventures, Supernode Global, DLF Ventures | Active | Partial |
| 74 | Proov | At-home reproductive hormone testing | $10M | 4 | April 2024 | Undisclosed | Angel | Ashanti, Nelly | Active | Partial |
| 75 | Dorsata | Obstetrics EHR workflow software | $9M | 3 | April 2020 | $5M | Series A | Women's Health USA, QED Investors, Labcorp | Active | Strong |
| 76 | Fertifa | Employee reproductive health benefits platform | $8M | 3 | June 2023 | $6M | Seed | Notion Capital, Triple Point Ventures, Speedinvest | Active | Strong |
| 77 | Hey Jane | Virtual reproductive and abortion care | $8M | 2 | October 2022 | $6M | Series A | Ulu Ventures, The Helm, Amboy Street Ventures | Active | Strong |
| 78 | BeSound | AI-enabled breast ultrasound screening | $7M | 1 | September 2025 | $7M | Seed | Kindred Ventures, Overwater Ventures, Muse Capital | Active | Full |
| 79 | Nua Surgical | C-section surgical retractor technology | $7M | 1 | December 2024 | $7M | Series A | EQT Life Sciences, TMC Venture Fund, Kidron Capital | Active | Full |
| 80 | BioAesthetics | Regenerative breast reconstruction grafts | $5M | 2 | December 2020 | $5M | Series A | FemHealth Ventures, Sandra Coufal, SOSV | Active | Partial |
| 81 | Conceive | Digital fertility coaching and support | $5M | 2 | August 2024 | $1M | Seed | Undisclosed | Active | Full |
| 82 | Escala Medical | Incision-free pelvic prolapse treatment | $5M | 3 | June 2025 | $4M | Series A | EIC Fund, private investors | Active | Partial |
| 83 | Fizimed | Connected pelvic-floor health devices | $5M | 2 | March 2025 | $4M | Series A | Bpifrance, UNIQA, UI Investissement | Active | Full |
| 84 | Gennev | Virtual menopause healthcare platform | $5M | 3 | August 2019 | $4M | Seed | BlueRun Ventures, Maven Ventures, StartUp Health | Acquired | Partial |
| 85 | Iron Health | Virtual extension for OB-GYN practices | $5M | 1 | March 2023 | $5M | Seed | Redesign Health, March of Dimes | Acquired | Full |
| 86 | Juno Bio | Vaginal microbiome diagnostics and testing | $5M | 3 | July 2026 | $4M | Venture | Ada Ventures, Artesian, Entrepreneur First | Active | Partial |
| 87 | Pelvital | At-home urinary incontinence treatment | $5M | 2 | April 2024 | $2M | Seed Plus | Boomerang Ventures, Pier 70 Ventures, Life Science Angels | Active | Full |
| 88 | TBD Health | Hybrid sexual and reproductive healthcare | $5M | 3 | February 2025 | Undisclosed | Seed | JourneyOne Ventures | Acquired | Partial |
| 89 | Apryl | Employer fertility and family benefits | $4M | 3 | April 2022 | $4M | Seed | Breega, Atlantic Labs, Crista Galli Ventures | Acquired | Partial |
| 90 | Béa Fertility | At-home fertility treatment devices | $4M | 4 | April 2026 | Undisclosed | Angel | Angel Academe | Active | Partial |
| 91 | Chiyo | Maternal nutrition and meal programs | $3M | 2 | March 2024 | $3M | Seed | Bread & Butter Ventures, Ingeborg, Union Heritage Ventures | Acquired | Strong |
| 92 | Partum Health | Pregnancy and postpartum care | $3M | 1 | September 2023 | $3M | Seed | True Wealth Ventures, MAGIC Fund, Everywhere Ventures | Active | Partial |
| 93 | Aster Health | AI EHR for women’s health | $3M | 2 | Month unknown 2024 | $0M | Follow-on / Undisclosed | Zeal Capital, Cornerstone VC, Octopus Ventures | Acquired | Partial |
| 94 | Cyrcadia Health | Wearable breast cancer monitoring | $3M | 5 | December 2015 | $0M | Venture / Equity | Undisclosed | Active | Low |
| 95 | Bird&Be | Fertility supplements and at-home tests | $2M | 2 | October 2025 | Undisclosed | Bridge / Seed Extension | HSR Ventures, Maggie Sellers Reum, Courtney Reum | Active | Partial |
| 96 | iSono Health | Automated wearable breast ultrasound | $2M | 3 | January 2026 | Undisclosed | Series A / Venture | Undisclosed | Active | Low |
| 97 | Uresta | Bladder leakage support device | $2M | 2 | March 2025 | $2M | Seed / Growth | NBIF, Women’s Equity Lab Atlantic, BDC Capital | Active | Low |
| 98 | Perifit | Connected pelvic floor training devices | $0M | 1 | June 2017 | $0M | Seed | Private investors | Active | Low |

This market map, featured in our femtech market deck, highlights top companies and startups in the femtech market
Key funding trends in the femtech market
Insights
- The top 10 femtech startups account for about 48% of the $4.51B represented in this ranking, showing that capital is concentrated at the top even though the market includes nearly 100 funded companies.
- Maven Clinic, Flo Health, and Midi Health have raised $937M combined, more than one fifth of all capital in the dataset, which highlights the fundraising power of scaled digital women’s healthcare platforms.
- Only 13 femtech startups have crossed $100M in cumulative funding, but these companies account for a large portion of sector capital, showing how quickly funding becomes concentrated once businesses reach institutional scale.
- Digital healthcare remains one of femtech’s strongest capital magnets. Maven Clinic, Midi Health, Pomelo Care, and Tia have raised about $970M combined across women’s, maternal, menopause, and primary care.
- Fertility and reproductive medicine infrastructure is another major funding cluster. TMRW Life Sciences, Gameto, ReproNovo, Natural Cycles, and Conceivable Life Sciences have attracted more than $590M in cumulative equity capital.
- Femtech diagnostics is becoming more capital intensive. Mercy BioAnalytics, PinkDx, Ataraxis AI, Teal Health, illumigyn, and Vara have collectively raised about $296M across cancer screening and diagnostic technologies.
- Recent rounds can radically change a femtech startup’s capitalization. Tia raised about 75% of its lifetime capital in one $100M Series B, while Peppy raised almost 79% in its $45M Series B.
- Large femtech financings no longer require long fundraising histories. ReproNovo raised $65M in a single Series A, while Comanche Biopharma accumulated $111M across only two documented financing rounds.
- Repeat fundraising still matters significantly. Companies with five or more rounds average far more cumulative capital than companies with shorter funding histories, showing how sustained institutional backing can separate the largest femtech businesses from the wider market.
- At least 19 companies in the ranking completed their latest financing between September 2025 and August 2026, showing that investment activity remains spread across digital care, fertility, diagnostics, therapeutics, and medical devices.

As this chart shows, and as featured in our femtech market deck, search interest in femtech has increased significantly
A few word about our methodology
As you can see, we built a database that ranks startups in the femtech market based on their total cumulative fundraising. To create this ranking, we reviewed many sources and cross-checked information across multiple places.
Whenever possible, we prioritized official company communications, since they are the most reliable source for funding amounts. When those were not available, we relied on reputable industry sources such as TechCrunch, Crunchbase, Financial Times or Forbes (to name a few).
We excluded random blogs, unverified websites, and any sources that could not be validated.
For femtech companies, we focused on equity financing connected to businesses whose core activities are centered on women’s health, reproductive health, fertility, maternal care, menopause, gynecology, women-focused diagnostics, or closely related technologies.
When funding rounds were announced in other currencies such as euros, Swiss francs, Singapore dollars, Australian dollars, or rupees, we converted them into approximate USD equivalents for consistency.
Sometimes different sources report slightly different numbers, or the exact round size is not fully disclosed. In those cases, we flag the uncertainty and assign a confidence label to each startup, visible in the last column.
Here is what they mean.
Full confidence: The company’s equity fundraising history can be reconstructed completely from public sources. The rounds, dates, amounts, and key investors are clearly identified, with no meaningful gaps.
Strong confidence: The fundraising history is largely complete and reliable. There may be a small missing detail, such as incomplete investor information or a minor round with limited data, but the overall record is clear.
Partial confidence: The main fundraising rounds can be identified, but the record is incomplete or somewhat mixed. Some rounds may be missing or certain funding events may be difficult to separate clearly.
Low confidence: Public information is too limited, inconsistent, or ambiguous to reliably reconstruct the company’s equity fundraising history.
When the confidence level is too low, we take a conservative approach and exclude the company from the ranking. We don’t want to include data that cannot be reliably verified.
This reflects how we conduct all our research, including the work behind our report covering the femtech market.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific calculation, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.

This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
Related blog posts
- Which companies are the most valued in the femtech market?
- How strong is fundraising in the femtech market right now?
- All the funding deals announced in the femtech market
- What are the key fundraising trends in the femtech market?
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.